Videos

Experts discuss the results of the CORE-001 Trial.

Experts compare Cretostimogene and BCG Administration Methods

"Pathogens can stay there for a long time, even if the contamination was really quick...It happens really fast," says Ana Lidia Flores-Mireles, PhD.

"We have incredible data based on long-term follow up that help us understand what the right therapy is for kids, primarily kids with neurologic diseases like spina bifida," says Rosalia Misseri, MD, FAAP.

"I think what's really important for this is that you counsel patients before they undergo testing," says Nicolette G. Payne, MD.

Key opinion leaders explore the role of androgen receptor-targeted therapy in mCRPC.

Key opinion leaders explore the expanding treament landscape for mCRPC.

“I think particularly as we've had the technology for longer and we've used it more and become more comfortable with it, there's really nobody, necessarily, that can't be considered for it,” says Aaron M. Bernie, MD, MPH.

"It looks like there are a lot of practices that are reticent about employing same-day discharge," says Brian R. Lane, MD, PhD, FACS.

“While we do see a decrease in opioid use, we still want to make sure that the pain is addressed and that it's addressed correctly,” says Laura Gressler, MS, PhD.

Prostate cancer management experts share their clinical insights on selecting appropriate serum, urine, and/or tissue biomarkers, highlighting specific scenarios that warrant each type of test.

The panel emphasizes the crucial need for swift biomarker and genetic testing to facilitate timely and effective patient care in prostate cancer management.

“The other thing that I think would be interesting is there's the thought of vasectomy regret where because of the permanent nature, what proportion of patients have regret surrounding their decision?” says Catherine S. Nam, MD.

"We sought to describe the genetic and clinical characteristics for patients undergoing genetic testing at our institution that were referred to genetics from our multidisciplinary stone clinic," says Nicolette G. Payne, MD.

“So, the concept behind delivering something orally in a spray is to hopefully avoid the whole GI effect and get faster absorption,” says Steven A. Kaplan, MD.

"We had a really clear idea...[We were looking at] how we can better optimize the system for cleaning," says Ana Lidia Flores-Mireles, PhD.

The panel outlines combination therapy options for patients with advanced prostate cancer and discusses the potential benefits of intensification of androgen deprivation therapy.

“I think the future is very bright for endourology and pushing the envelope with different minimally invasive techniques to remove stones,” says Marcelino E. Rivera, MD.

Experts on prostate cancer discuss factors to consider while making treatment decisions for patients with nonmetastatic castration-sensitive prostate cancer.

“Within our department at University of Michigan, there has been increased numbers of vasectomy procedure days to be able to meet the demand so that there's not a very long prolonged delay for our patients,” says Catherine S. Nam, MD.

"We've really found that [same-day discharge is] a reasonable option and something that many patients are really pleased by," says Brian R. Lane, MD, PhD, FACS.

Experts discuss the patient quantity and qualifications for the CORE-001 trial.

Experts give an overview of the ASCO 2024 data.

“We need formal recommendations for nonopioid pain management strategies and medications,” says Laura Gressler, MS, PhD.

“The hope is that the research and technology will be mature enough at the time that they're ready to use that tissue for a biological child,” says Amanda J. Saraf, DO.

"What we think is really nice about it is it's not required to have it into an electronic medical record for this to work on the wards," says Jennifer Ann Meddings, MD.

“It will be interesting to see how this plays out long-term in the changing political scheme, as well as the general trend of the current generation potentially having different thoughts in terms of wanting to have children or not in the future,” says Catherine S. Nam, MD.

“We believe this is going to be the next rendition of how we can train physicians, as well as make surgeons more effective at their job,” says Nitin K. Yerram, MD.

"If we want to do a targeted therapy, we have to know exactly where and what we are treating," says Gamal M. Ghoniem, MD, FACS, ABU/FPMRS.

The key opinion leaders explore the challenges and limitations associated with using prostate-specific antigen (PSA) as a biomarker for prostate cancer detection and monitoring.